IsoPlexis uses proteomics to identify early factors of long COVID
IsoPlexis has published a study in Cell, led by the Institute for Systems Biology and the Seattle COVID Consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as post-acute sequelae of COVID-19 (PASC) or long COVID. Read More
Twist Bioscience, Eleven Therapeutics create replicon for antiviral development
Twist Bioscience and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening as well as vaccine and therapeutic development. Read More
Novavax COVID-19 vaccine approved in Great Britain
Novavax announced that the Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for its Nuvaxovid COVID-19 vaccine for active immunization in individuals 18 years of age and older in Great Britain. The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine to be authorized for use in Great Britain. Read More
Novavax submits EUA request to FDA for COVID-19 vaccine
Novavax submitted a request to the U.S Food and Drug Administration (FDA) for emergency use authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for the immunization of individuals 18 years of age and older against SARS-CoV-2. Read More
NTx obtains grant to improve mRNA therapy manufacturing, access
NTx has received a grant from the Bill & Melinda Gates Foundation to advance novel solutions for mRNA production and related supply chain challenges. Read More
Anixa Biosciences, MolGenie announce SARS-CoV-2 protease inhibitor
Anixa Biosciences and its partner MolGenie have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting the main protease of the SARS-CoV-2 virus. Read More
FDA expands use of remdesivir to outpatients with mild-to-moderate COVID-19
The U.S. Food and Drug Administration (FDA) has expanded the use of the antiviral drug Veklury (remdesivir) to certain nonhospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. Read More
Vir Biotechnology begins antibody research focused on HIV, malaria
Vir Biotechnology has expanded its partnership with the Bill & Melinda Gates Foundation to advance innovative platform technologies in the development of broadly neutralizing antibodies that provide a vaccinal effect for the treatment of HIV and the prevention of malaria. Read More
PostEra closes $24M in new financing to advance drug discovery
PostEra has closed $24 million in equity financing to accelerate medicinal chemistry and bring new cures to patients. The company also announced a multitarget strategic partnership with Pfizer to establish an artificial intelligence lab. Read More
Pfizer collaborates with Acuitas, Beam Therapeutics
Pfizer and Acuitas Therapeutics have entered into a development and option agreement under which Pfizer may license on a nonexclusive basis Acuitas' liquid nanoparticle technology for up to 10 targets for vaccine or therapeutic development. Also, Pfizer and Beam Therapeutics entered into an exclusive four-year research collaboration focused on in vivo base-editing programs for three targets for rare genetic diseases of the liver, muscle, and central nervous system. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter